Cited by 1,515Blood Pressure and Hypertension StudiesDiabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Metformin: An Old Drug for the Treatment of Diabetes But a New Drug for the Protection of the Endothelium

Open access
Kinaan, Mustafa, Ding, Hong, Triggle, Chris R.·2015·Medical Principles and Practice

Abstract

OBJECTIVE: To determine whether tight control of blood pressure prevents macrovascular and microvascular complications in patients with type 2 diabetes. DESIGN: Randomised controlled trial comparing tight control of blood pressure aiming at a blood pressure of <150/85 mm Hg (with the use of an angiotensin converting enzyme inhibitor captopril or a beta blocker atenolol as main treatment) with less tight control aiming at a blood pressure of <180/105 mm Hg. SETTING: 20 hospital based clinics in England, Scotland, and Northern Ireland. SUBJECTS: 1148 hypertensive patients with type 2 diabetes (mean age 56, mean blood pressure at entry 160/94 mm Hg); 758 patients were allocated to tight control of blood pressure and 390 patients to less tight control with a median follow up of 8.4 years. MAIN OUTCOME MEASURES: Predefined clinical end points, fatal and non-fatal, related to diabetes, deaths related to diabetes, and all cause mortality. Surrogate measures of microvascular disease included urinary albumin excretion and retinal photography. RESULTS: Mean blood pressure during follow up was significantly reduced in the group assigned tight blood pressure control (144/82 mm Hg) compared with the group assigned to less tight control (154/87 mm Hg) (P<0.0001). Reductions in risk in the group assigned to tight control compared with that assigned to less tight control were 24% in diabetes related end points (95% confidence interval 8% to 38%) (P=0.0046), 32% in deaths related to diabetes (6% to 51%) (P=0.019), 44% in strokes (11% to 65%) (P=0.013), and 37% in microvascular end points (11% to 56%) (P=0.0092), predominantly owing to a reduced risk of retinal photocoagulation. There was a non-significant reduction in all cause mortality. After nine years of follow up the group assigned to tight blood pressure control also had a 34% reduction in risk in the proportion of patients with deterioration of retinopathy by two steps (99% confidence interval 11% to 50%) (P=0.0004) and a 47% reduced risk (7% to 70%) (P=0.004) of deterioration in visual acuity by three lines of the early treatment of diabetic retinopathy study (ETDRS) chart. After nine years of follow up 29% of patients in the group assigned to tight control required three or more treatments to lower blood pressure to achieve target blood pressures. CONCLUSION: Tight blood pressure control in patients with hypertension and type 2 diabetes achieves a clinically important reduction in the risk of deaths related to diabetes, complications related to diabetes, progression of diabetic retinopathy, and deterioration in visual acuity.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1159/000381643

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • When prescribed in the usual oral dosage range of 250 to ~2550 mg/day for T2DM and in the absence of reduced renal function, peak plasma levels of metformin are unlikely to exceed 15-20 μM, with trough levels between 1-5 μM, and a plasma half-life of approximately 3 to 5 hours.

    “When prescribed in the usual oral dosage range of 250 to ~2550 mg/day for the treatment of T2DM and in the absence of reduced renal function, it is unlikely that peak plasma levels of metformin would exceed 15-20 μM, with trough levels of between 1-5 μM, and a plasma half-life of approximately 3 to 5 hours.”
  • With a plasma half-life of approximately 3 to 5 hours and subject to dosing schedule, it is unlikely that other than in gut enterocytes a significant cellular accumulation of metformin occurs when used for T2DM.

    “However, with a plasma half-life of approximately 3 to 5 hours, and subject to the schedule of dosing, it is unlikely, that other than in gut enterocytes, a significant cellular accumulation of metformin occurs when the drug is used for the treatment of T2DM (34, 155, 156, 159, 160).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 178 · Cited by 1,515

Authors
Kinaan, M., Ding, H., & Triggle, C. R.
Affiliations
Weill Cornell Medical College in Qatar (QA)
Corresponding author
Triggle, Chris R.
Venue
Medical Principles and Practice
Publisher
S. Karger AG
Published
2015
Volume
24
Issue
5
Pages
401-415
ISSN
  • 1011-7571 (ISSN-L)
  • 1423-0151
OpenAlex
W1545732697
Cited by
1,515
References
178
Citations by year
2026: 2 · 2025: 19 · 2024: 56 · 2023: 90 · 2022: 101 · 2021: 68 · 2020: 62 · 2019: 75 · 2018: 95 · 2017: 107 · 2016: 111 · 2015: 111 · 2014: 50 · 2013: 28 · 2012: 29
FWCI
24.39
Type
journal article
Language
en
Open access
Locations
  • Medical Principles and Practice (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
Wellcome Trust
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
Keywords
tight blood pressure control, type 2 diabetes, hypertension, microvascular complications, macrovascular complications, retinopathy, diabetic nephropathy, albuminuria, stroke, captopril, atenolol, ACE inhibitors, beta-blockers, endothelial protection, metformin, all-cause mortality, cardiovascular risk reduction, retinal photocoagulation, retinopathy progression
MeSH terms
Adenylyl Cyclases, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Endothelium, Gluconeogenesis, Humans, Metformin, Mitochondria, Neoplasms, Protein Kinase C, Retrospective Studies, Vascular Diseases, Signal Transduction, Glycation End Products, Advanced, Sirtuins, Glucose Transporter Type 4, AMP-Activated Protein Kinases, TOR Serine-Threonine Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review